| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(12)61084-8 |
| P698 | PubMed publication ID | 23063316 |
| P50 | author | Jean-Frédéric Colombel | Q30248037 |
| Gert Van Assche | Q37064266 | ||
| Javier P Gisbert | Q37829251 | ||
| Martti Färkkilä | Q42383672 | ||
| Maria Esteve | Q43124466 | ||
| Maria Nachury | Q56850575 | ||
| P2093 | author name string | Denis Franchimont | |
| Philippe Marteau | |||
| Jean-Yves Mary | |||
| Franck Carbonnel | |||
| Jacques Moreau | |||
| Julien Branche | |||
| Guillaume Savoye | |||
| Yoram Bouhnik | |||
| Jacques Cosnes | |||
| Jean-Charles Delchier | |||
| Elena Ricart | |||
| Arnaud Bourreille | |||
| Matthieu Allez | |||
| David Laharie | |||
| Jean-Louis Dupas | |||
| Gilles Bommelaer | |||
| Xavier Roblin | |||
| Frank Zerbib | |||
| Benoit Coffin | |||
| Marc Lémann | |||
| Olivier Dewit | |||
| Antonio Lopez-Sanroman | |||
| Jerome Filippi | |||
| Martine de Vos | |||
| Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives | |||
| Stephane Nahon | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis | Q33307776 | ||
| Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee | Q33523446 | ||
| European evidence-based Consensus on the management of ulcerative colitis: Current management | Q34025054 | ||
| Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
| THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. | Q34478028 | ||
| Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. | Q35595821 | ||
| Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis | Q35760789 | ||
| The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications | Q36477912 | ||
| Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. | Q36793930 | ||
| The pattern and outcome of acute severe colitis | Q37814560 | ||
| Power and sample size calculations. A review and computer program | Q37879786 | ||
| Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis | Q43582796 | ||
| Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis | Q43734542 | ||
| Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis | Q43798421 | ||
| Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study | Q44517208 | ||
| Infliximab efficacy in pediatric ulcerative colitis | Q45285885 | ||
| Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
| A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization | Q46846798 | ||
| Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 | ||
| Cortisone in ulcerative colitis; final report on a therapeutic trial. | Q55499879 | ||
| Ulcerative Colitis | Q55922642 | ||
| Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man | Q57265461 | ||
| Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study | Q68206432 | ||
| Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years | Q79676507 | ||
| Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up | Q80793210 | ||
| European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease | Q82963520 | ||
| P433 | issue | 9857 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| cyclosporine | Q367700 | ||
| P304 | page(s) | 1909-1915 | |
| P577 | publication date | 2012-10-10 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | |
| P478 | volume | 380 |
| Q90619145 | 2019 Expert opinion on biological treatment use in inflammatory bowel disease management |
| Q38287132 | A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. |
| Q35973766 | A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease |
| Q34353032 | A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases |
| Q92690822 | AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis |
| Q92690717 | AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis |
| Q38204993 | Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis |
| Q38942561 | Acute severe ulcerative colitis: from pathophysiology to clinical management |
| Q49232336 | Acute severe ulcerative colitis: latest evidence and therapeutic implications |
| Q26798299 | Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 |
| Q38130044 | Advances in the medical management of paediatric IBD. |
| Q38816194 | Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. |
| Q92226508 | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis |
| Q38961202 | B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. |
| Q38630959 | Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. |
| Q92410206 | Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia |
| Q38568898 | Biologic agents for IBD: practical insights |
| Q31017419 | Biologics in inflammatory bowel disease: what are the data? |
| Q26999078 | Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q38432470 | CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. |
| Q52346955 | Chinese research into severe ulcerative colitis has increased in quantity and complexity. |
| Q52673722 | Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. |
| Q38443024 | Clinical trials in ulcerative colitis: a historical perspective |
| Q44641895 | Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab? |
| Q89623411 | Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis |
| Q40425878 | Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study |
| Q50097248 | Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. |
| Q46201026 | Comparison of mortality following hospitalisation for ulcerative colitis in Scotland between 1998-2000 and 2007-2009. |
| Q52626302 | Contemporary Management of Ulcerative Colitis. |
| Q89061132 | Contemporary Medical Management of Acute Severe Ulcerative Colitis |
| Q38293796 | Conventional drug therapy for inflammatory bowel disease |
| Q36815176 | Cost utility of inflammation-targeted therapy for patients with ulcerative colitis |
| Q64269853 | Curcumin and resveratrol suppress dextran sulfate sodium‑induced colitis in mice |
| Q34809305 | Current and emerging biologics for ulcerative colitis |
| Q39098635 | Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. |
| Q43139980 | Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis? |
| Q38126004 | Drug advances in inflammatory bowel disease |
| Q38365426 | Early investigational TNF receptor antagonists for the treatment of ulcerative colitis |
| Q89260034 | Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis |
| Q35777883 | Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis |
| Q38662186 | Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. |
| Q36637710 | Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience |
| Q26768270 | Elderly patients and inflammatory bowel disease |
| Q89540272 | Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases |
| Q38258954 | European evidence based consensus on surgery for ulcerative colitis |
| Q50079201 | Evidence-based clinical practice guidelines for inflammatory bowel disease. |
| Q38724227 | Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. |
| Q47849060 | Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study |
| Q36615081 | First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis |
| Q89459590 | First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician |
| Q39085361 | Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis |
| Q26866110 | Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications |
| Q64062261 | Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? |
| Q92025298 | Head-to-head trials in inflammatory bowel disease: past, present and future |
| Q38253145 | How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? |
| Q48200915 | Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study |
| Q38838173 | Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series |
| Q38072282 | IBD in 2012: Pathogenesis and management of IBD--thinking outside the box. |
| Q56973177 | IBD. Sequential rescue therapy in steroid-refractory ulcerative colitis |
| Q40181878 | Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study |
| Q26771136 | Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis |
| Q40430505 | Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation |
| Q39841706 | Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. |
| Q53241323 | Inflammatory Bowel Disease. |
| Q47961270 | Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches |
| Q38609076 | Inflammatory bowel disease in the UK: is quality of care improving? |
| Q90331029 | Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease |
| Q89986502 | Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis |
| Q27005445 | Inflammatory pathways of importance for management of inflammatory bowel disease |
| Q41266366 | Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis |
| Q46875109 | Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. |
| Q64121962 | Infliximab in inflammatory bowel disease |
| Q42381018 | Infliximab or ciclosporin for acute severe ulcerative colitis? |
| Q36037115 | Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. |
| Q37196938 | Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial |
| Q45947185 | Infliximab versus ciclosporin in severe ulcerative colitis. |
| Q38117175 | Investigational cytokine-targeted therapies for ulcerative colitis. |
| Q90724329 | Korean Traditional Medicine (Jakyakgamcho-tang) Ameliorates Colitis by Regulating Gut Microbiota |
| Q90136814 | Landmark studies and emerging strategies for the management of acute severe ulcerative colitis |
| Q43534755 | Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided; authors' reply |
| Q48094924 | Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply. |
| Q38694769 | Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. |
| Q61911786 | Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response—An Observational Study |
| Q44478513 | Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications. |
| Q36167512 | MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. |
| Q38848140 | Maintenance therapy options for ulcerative colitis. |
| Q91817020 | Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules |
| Q34508900 | Management of acute severe ulcerative colitis |
| Q38102982 | Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab |
| Q38321528 | Management of severe ulcerative colitis |
| Q33819473 | Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease |
| Q42116204 | Managing acute severe ulcerative colitis in the hosptialised setting |
| Q26777729 | Medical Therapy of Active Ulcerative Colitis |
| Q33958740 | Need for infliximab dose intensification in Crohn's disease and ulcerative colitis |
| Q38670811 | New treatment strategies for ulcerative colitis |
| Q41949151 | Novel treatment options for ulcerative colitis |
| Q102049664 | Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia |
| Q26866940 | Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease |
| Q38687407 | Optimizing pharmacologic management of inflammatory bowel disease |
| Q39338382 | Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up |
| Q30664895 | Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit |
| Q48161573 | Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis |
| Q38542903 | Positioning Therapy for Ulcerative Colitis |
| Q57167308 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases |
| Q90656536 | Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis |
| Q38286166 | Predicting outcomes in acute severe ulcerative colitis |
| Q37106707 | Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors |
| Q38117907 | Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis |
| Q36249551 | Protective Effect of Calculus Bovis Sativus on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice |
| Q43190589 | Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? |
| Q37054120 | Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response |
| Q28657925 | Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT) |
| Q38815035 | Recent trends and future directions for the medical treatment of ulcerative colitis. |
| Q92798584 | Remicade® (infliximab): 20 years of contributions to science and medicine |
| Q50942285 | Rescue therapy: ciclosporin or infliximab? |
| Q34528270 | Review article: acute severe ulcerative colitis - evidence-based consensus statements. |
| Q26823221 | Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis |
| Q30239077 | Review article: dose optimisation of infliximab for acute severe ulcerative colitis |
| Q35883580 | Review article: the practical management of acute severe ulcerative colitis |
| Q26992012 | Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future |
| Q39251794 | Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis |
| Q38230163 | Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. |
| Q88677985 | Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients |
| Q43611596 | Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients |
| Q98386851 | Simple water-based tacrolimus enemas for refractory proctitis |
| Q64107563 | Surgery in the age of biologics |
| Q38575522 | Surgical and medical treatment in patients with acute severe ulcerative colitis |
| Q38726448 | Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids |
| Q61821109 | Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis |
| Q90395393 | Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis |
| Q38404037 | Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks? |
| Q37044321 | Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis |
| Q26997361 | Tacrolimus for the Treatment of Ulcerative Colitis |
| Q31004717 | Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study |
| Q38160905 | Targeting TNF-α for the treatment of inflammatory bowel disease |
| Q39037681 | The biologics of ulcerative colitis |
| Q60017517 | The current state of the art for biological therapies and new small molecules in inflammatory bowel disease |
| Q44033640 | The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients |
| Q91645954 | The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor |
| Q38121000 | The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy |
| Q38180807 | Therapeutic peptides in inflammatory bowel disease |
| Q38778842 | There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. |
| Q42695266 | Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? |
| Q37576428 | Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial |
| Q38285619 | Treatment of IBD: where we are and where we are going |
| Q64236406 | Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial |
| Q41894047 | Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis |
| Q38258440 | Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? |
| Q55214747 | Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis. |
| Q92443656 | Ulcerative Colitis: Current and Emerging Treatment Strategies |
| Q38331566 | Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? |
| Q88899916 | Ulcerative colitis |
| Q38217653 | Ulcerative colitis: current pharmacotherapy and future directions. |
| Q38211425 | Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166). |
| Q47252968 | Ulcerative colitis: management in adults, children and young people - concise guidance . |
| Q85643166 | Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? |
| Q39102244 | Update on the Use of Biologic Therapy in Ulcerative Colitis |
| Q40777140 | Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis |
| Q33732010 | Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis. |
| Q50629702 | Vedolizumab: a novel treatment for ipilimumab-induced colitis. |
| Q50131636 | Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis |
| Q50483940 | [New advances in the treatment of inflammatory bowel disease]. |
| Q50483943 | [Safety in the diagnosis and treatment of inflammatory bowel disease]. |
| Q87404464 | [Therapy of chronic inflammatory bowel diseases. Standards, controversies and perspectives] |
Search more.